Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Next Previous
X
Search
Trial Profile

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talquetamab (Primary) ; Talquetamab (Primary) ; Recombinant human serum albumin
  • Indications Multiple myeloma
  • Focus First in man; Registrational; Therapeutic Use
  • Acronyms MonumenTAL-1
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 09 Oct 2024 Planned End Date changed from 31 Dec 2026 to 8 Jan 2027.
    • 01 Oct 2024 Results assessing the efficacy and safety of Talquetamab published in the Clinical Lymphoma, Myeloma & Leukemia.
    • 28 Jun 2024 Planned number of patients changed from 450 to 480.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top